What's happening now has happened with every other
Post# of 15624
Once the Q's start showing revenue from commercialization, then at least for a while the price should stabilize. And that's only for the cream. The sublingual tablet could again throw the stock into the run->retrace mode until commercialization of that.
If the price could get to around $1.50 before results, that would be a good launching point.